QURE · XBRL financial data

uniQure financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (QURE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	3	25	1	0	1	2
Research and development	122	144	198	215	144	141
Selling, general and administrative	43	56	55	75	53	65
Operating income (loss)	(125)	311	(143)	(283)	(184)	(185)
Interest income	1	0	1	20	21	17
Interest expense	4	7	12	42	64	62
Other income (expense)	0	(0)	3	—	—	11
Income tax expense (benefit)	(16)	3	(1)	2	2	6
Net income (loss)	—	—	—	(308)	(240)	(199)
Earnings per share, basic USD per share	(2.81)	7.17	(2.71)	(6.47)	(4.92)	(3.46)
Earnings per share, diluted USD per share	(2.81)	7.04	(2.71)	(6.47)	(4.92)	(3.46)
Weighted average shares, basic millions of shares	44	46	47	48	49	58
Weighted average shares, diluted millions of shares	44	47	47	48	49	58

Fiscal years (QURE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	245	556	228	241	159	80
Marketable securities	—	—	—	377	209	543
Accounts receivable	7	—	—	—	—	6
Inventory	—	—	7	12	—	—
Total current assets	259	628	477	652	390	656
Property and equipment, net	32	44	51	47	20	14
Right-of-use asset	26	26	33	29	14	13
Goodwill	1	28	26	26	22	25
Total assets	340	809	705	832	557	825
Accounts payable	4	3	11	7	7	5
Accrued liabilities	18	28	31	31	29	41
Total current liabilities	27	37	76	74	40	63
Long-term debt	36	101	103	102	51	50
Lease liability, non-current	30	29	32	28	11	10
Total liabilities	96	213	229	624	563	626
Accumulated deficit	(785)	(455)	(582)	(890)	(1,130)	(1,329)
Total stockholders' equity	244	596	476	208	(7)	199
Total liabilities and equity	340	809	705	832	557	825
Common shares outstanding (cover page) millions of shares	45	46	47	48	54	63

Fiscal years (QURE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	—	—	(308)	(240)	(199)
Stock-based compensation	22	26	34	35	22	18
Net cash from operating activities	(135)	288	(145)	(146)	(183)	(178)
Purchases of property and equipment	7	17	18	7	3	0
Net cash from investing activities	(9)	(67)	(183)	(206)	163	(322)
Proceeds from issuing common stock	7	3	—	—	—	—
Proceeds from long-term debt	—	64	—	—	—	—
Repayments of long-term debt	—	—	—	—	53	—
Net cash from financing activities	7	95	1	363	(59)	415
Net change in cash	(133)	312	(328)	13	(84)	(79)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	70	27	2.6*	79.2M	—	Q3 FY26 10-QSep 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.